Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Small Cell Lung Carcinoma
- Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04173325
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Nagla A Karim, MD, PhD Augusta University Georgia Cancer Center